Literature DB >> 27497856

Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group.

Ronald S Go1, Jeffrey L Winters2, Nelson Leung3, David L Murray2, Maria A Willrich2, Roshini S Abraham2, Hatem Amer3, William J Hogan4, Ariela L Marshall4, Sanjeev Sethi2, Cheryl L Tran5, Dong Chen2, Rajiv K Pruthi4, Aneel A Ashrani4, Fernando C Fervenza3, Carl H Cramer5, Vilmarie Rodriguez6, Alexandra P Wolanskyj4, Stephan D Thomé7, C Christopher Hook8.   

Abstract

Thrombotic microangiopathies (TMAs) comprise a heterogeneous set of conditions linked by a common histopathologic finding of endothelial damage resulting in microvascular thromboses and potentially serious complications. The typical clinical presentation is microangiopathic hemolytic anemia accompanied by thrombocytopenia with varying degrees of organ ischemia. The differential diagnoses are generally broad, while the workup is frequently complex and can be confusing. This statement represents the joint recommendations from a multidisciplinary team of Mayo Clinic physicians specializing in the management of TMA. It comprises a series of evidence- and consensus-based clinical pathways developed to allow a uniform approach to the spectrum of care including when to suspect TMA, what differential diagnoses to consider, which diagnostic tests to order, and how to provide initial empiric therapy, as well as some guidance on subsequent management.
Copyright © 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27497856     DOI: 10.1016/j.mayocp.2016.05.015

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  16 in total

Review 1.  Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP).

Authors:  Jeffrey L Winters
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  The Novel Coronavirus and Haemostatic Abnormalities: Pathophysiology, Clinical Manifestations, and Treatment Recommendations.

Authors:  S Louw; B F Jacobson; E S Mayne; T M Wiggill
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  A rare case of thrombotic microangiopathy triggered by acute pancreatitis.

Authors:  Kevin Singh; Ahmed Jamal Nadeem; Behzad Doratotaj
Journal:  BMJ Case Rep       Date:  2017-05-15

4.  Quetiapine-induced thrombotic microangiopathy in a patient on maintenance dialysis.

Authors:  Miki Takahashi; Akihito Deguchi; Hiromu Nishihara; Mea Asou; Tomohiko Asakawa; Makoto Araki
Journal:  CEN Case Rep       Date:  2020-09-27

Review 5.  The Complement Alternative Pathway and Preeclampsia.

Authors:  Layan Alrahmani; Maria Alice V Willrich
Journal:  Curr Hypertens Rep       Date:  2018-05-01       Impact factor: 5.369

6.  Atypical Hemolytic Uremic Syndrome: Genetic Landscape Challenge.

Authors:  Laura Valiña; Bernardo López Andrade; Josep Miquel Bauça
Journal:  EJIFCC       Date:  2019-10-11

7.  Severe primary refractory thrombotic thrombocytopenic purpura (TTP) in the post plasma exchange (PEX) and rituximab era.

Authors:  Sowmya Goranta; Smit S Deliwala; Tarek Haykal; Ghassan Bachuwa
Journal:  BMJ Case Rep       Date:  2020-06-11

8.  A rare case of renal thrombotic microangiopathy associated with Castleman's disease.

Authors:  Anubha Mutneja; L Nicholas Cossey; Helen Liapis; Ying Maggie Chen
Journal:  BMC Nephrol       Date:  2017-02-10       Impact factor: 2.388

9.  Impact of a multidisciplinary team for the management of thrombotic microangiopathy.

Authors:  Miguel G Uriol Rivera; Sheila Cabello Pelegrin; Carmen Ballester Ruiz; Bernardo López Andrade; Javier Lumbreras; Aina Obrador Mulet; Albert Perez Montaña; Mireia Ferreruela Serlavos; José Ignacio Ayestarán Rota; Joana Ferrer Balaguer; Olga Delgado Sanchez; Lucio Pallares Ferreres; Antonio Mas Bonet; María Jose Picado Valles; Rosa María Ruíz de Gopegui Valero
Journal:  PLoS One       Date:  2018-11-02       Impact factor: 3.240

10.  When to consider targeted therapies in thrombotic microangiopathies in the modern era: walking the tightrope between cost, safety, and efficacy.

Authors:  Catherine R Murphree; Sven R Olson; Thomas G DeLoughery; Joseph J Shatzel
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.